Dynamic monitoring of the intestinal barrier with Confocal Laser Endomicroscopy demonstrated to be far superior to endoscopic and histologic...
Global 9-month sales slightly down (5%) at €4.8 million while sales in the United States grew 23% Mauna Kea Technologies today announced...
Mauna Kea Technologies today announces the appointment of Sacha Loiseau, Founder and current Chairman of the Board of Mauna Kea Technologies, to...
Mauna Kea Technologies postpones release of its 2022 Half-Year Results, which was originally planned for September 22, 2022, to not later than...
Results of the 20-patient study published in the European Journal of Nuclear Medicine and Molecular Imaging demonstrated the potential for high...
Stable YTD Revenue while Strategic Realignment Implemented 35% 1H U.S. Sales Growth offset by Declines in Asia Recently announced Tasly...
Mauna Kea to form Joint Venture (JV) with Tasly to develop, manufacture and commercialize Cellvizio for the Chinese market. JV also to acquire...
Results demonstrate a significant increase in the detection rate of neoplasia when Cellvizio is used as an adjunct to the standard of care,...
Study published in Nature Communications finds cancer-targeted molecular imaging agent with needle-based confocal laser endomicroscopy system...
Following its 2021 restructuring, Company experiences stable U.S sales growth, including improved gross margin and anticipated reductions in...
Completion of a Major Regulatory Milestone for Molecular Imaging and Precision Medicine as Part of Ongoing Collaboration Mauna Kea...
